T
Tereza Lanitis
Researcher at St. Michael's Hospital
Publications - 16
Citations - 335
Tereza Lanitis is an academic researcher from St. Michael's Hospital. The author has contributed to research in topics: Cost effectiveness & Apixaban. The author has an hindex of 8, co-authored 15 publications receiving 279 citations.
Papers
More filters
Journal ArticleDOI
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
Paul Dorian,Thitima Kongnakorn,Hemant Phatak,Dale Rublee,Andreas Kuznik,Tereza Lanitis,Larry Z. Liu,Uchenna H. Iloeje,Luis Hernandez,Gregory Y.H. Lip +9 more
TL;DR: Based on randomized trial data, apixaban is a cost-effective alternative to warfarin and aspirin, in VKA suitable and VKA unsuitable patients with AF, respectively.
Journal ArticleDOI
Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Gregory Y.H. Lip,Thitima Kongnakorn,Hemant Phatak,Andreas Kuznik,Tereza Lanitis,Larry Z. Liu,Uchenna H. Iloeje,Luis Hernandez,Paul Dorian +8 more
TL;DR: It is projected that apixaban may be a cost-effective alternative to dabigatran 150 mg BID, dabig atran 110 mg BIDs, and rivaroxaban 20 mg once daily for stroke prevention in AF patients from the perspective of the United Kingdom National Health Services.
Journal ArticleDOI
Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
TL;DR: Probabilistic sensitivity analyses indicate that apixaban is an optimal treatment option compared with warfarin and aspirin, when the willingness-to-pay is above SEK 35,000 and SEK 45,000 per QALY, respectively.
Journal ArticleDOI
Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin
Thitima Kongnakorn,Tereza Lanitis,Lieven Annemans,Vincent Thijs,Marnix Goethals,Sophie Marbaix,Jean-Claude Wautrecht +6 more
TL;DR: Amongst NOACs, apixaban may be the most economically efficient alternative to warfarin in NVAF patients who are suitable for VKA treatment and eligible for stroke prevention in Belgium.
Journal ArticleDOI
Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-effectiveness Analysis.
TL;DR: IAI 2q8 can be cost saving and cost-effective compared with Rq4 and ranibizumab PRN for the treatment of wAMD in the United States.